Aura Biosciences Inc (NASDAQ:AURA) – Stock analysts at SVB Leerink issued their Q3 2021 earnings estimates for shares of Aura Biosciences in a research note issued on Tuesday, November 23rd. SVB Leerink analyst A. Berens anticipates that the company will earn ($0.51) per share for the quarter. SVB Leerink has a “Outperform” rating and a $40.00 price target on the stock. SVB Leerink also issued estimates for Aura Biosciences’ Q4 2021 earnings at ($0.38) EPS, FY2021 earnings at ($3.40) EPS, FY2022 earnings at ($1.74) EPS, FY2023 earnings at ($2.57) EPS, FY2024 earnings at ($3.63) EPS and FY2025 earnings at ($4.44) EPS.
Other equities research analysts have also recently issued reports about the company. BTIG Research began coverage on Aura Biosciences in a research note on Tuesday. They issued a “buy” rating and a $38.00 target price on the stock. Cowen assumed coverage on Aura Biosciences in a research report on Tuesday. They set an “outperform” rating for the company. Finally, Evercore ISI began coverage on shares of Aura Biosciences in a research report on Tuesday. They issued an “outperform” rating and a $35.00 target price for the company.
Aura Biosciences Company Profile
Aura Biosciences Inc is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system. The company’s lead product candidate includes AU-011. Aura Biosciences Inc is based in CAMBRIDGE, Mass.
Featured Article: VIX – Volatility Index
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.